The United States is global powerhouse in pharmaceutical contract development and manufacturing, home to some of the world’s most advanced CDMOs. The U.S. combines scale, scientific leadership, and advanced regulatory infrastructure to support drug development from early-stage innovation to commercial manufacturing.
The U.S. currently leads biomedical research globally, conducting roughly 46% of all life‑sciences R&D. The contract manufacturing market in the United States is expected to reach $68.32 Billion USD by 2029. Read the full article here.